First targeted protein degrader hits the clinic

New therapeutics that harness cellular machinery to degrade targets are entering clinical trials, led by a PROTAC anticancer candidate developed by Arvinas.

Search for this author in:

A targeted degrader (multicoloured) binds a target (green) and an E3 ligase (blue), to drive ubiquitylation (purple) and degradation by the proteasome (orange). Credit: Arvinas.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Nature Reviews Drug Discovery 18, 237-239 (2019)

doi: 10.1038/d41573-019-00043-6

Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.